A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Pancreatic Cancer
PANCREATIC CANCER ADVISOR
FEATURED CONTENT
-
-
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions. -
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection. -
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate. -
Treatment Options for Pancreatic Neuroendocrine Tumors
In the management of PNETs it is important to differentiate between functional and nonfunctional PNETs in order to determine the course of treatment.
PANCREATIC CANCER NEWS
Neoadjuvant Treatment of Borderline-Resectable Pancreatic Cancer Led to Improved Overall Survival
New-Onset Type 2 Diabetes as a Potential Biomarker in Pancreatic Cancer
Clinical, Genetic, Biomarker Model IDs Risk for Pancreatic Cancer
Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report
Addition of PEGPH20 to Frontline Chemotherapy Did Not Improve Clinical Outcomes in Pancreatic Cancer Subgroup
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
